Health
Alzheimer’s disease in the EU during and after pandemic
The COVID-19 pandemic has had a severe impact on health services across the EU and one public health condition that was sidelined, among others, was Alzheimer’s disease. The World Health Organisation (WHO) has spotted serious malfunctioning in dementia diagnosis and...
An animal-free path towards EU’s sustainable chemical ambitions
Presented in October 2020, the EU chemicals strategy for sustainability is intended as a first step towards a zero pollution ambition for a toxic-free environment as a key part of the European Green Deal. While its unveiling was widely welcomed...
Diabetes in the EU between awareness and access to care
Diabetes remains a major public health concern despite the efforts to increase awareness and reverse its relentless spread in Europe.
Life with SMA: challenges and solutions
Despite steady advancements in the past years, gaps in Spinal Muscular Atrophy (SMA) care persist across the bloc.
The future of biotech in Europe
A fairly recent but already fast-growing industry, the biotech sector seeks to claim a role in Europe as a catalyst for growth in the aftermath of the COVID-crisis.
Metastatic Breast Cancer: Still a lot to be done
Although there is no cure for metastatic breast cancer (MBC), pharma innovation has helped to increase survivorship. However, patients with MBC face a number of challenges and inequalities across Europe, from screening to social discrimination and lack of knowledge.
Alzheimer’s disease tests EU readiness
Alzheimer’s disease and other dementias affect each individual in different ways but early detection is always key for effective treatment.
From vaccine race to marathon: What’s next for coping with COVID?
The COVID-19 virus is not going anywhere any time soon and, as new variants keep cropping up across the globe, vaccine development cannot afford to stand still. There are currently just over 100 vaccines in clinical development worldwide but only...
From words to action: Exploring the ecosystem of antimicrobial resistance
Antimicrobial resistance (AMR) is the ability of microorganisms to evolve to resist antibiotics, leading to infections becoming increasingly untreatable. AMR already claims as many as 33,000 lives in the EU every year, but this is set to drastically worsen, with...
Europe’s ‘decade of the kidney’
From improving the availability of all treatment options to the development of home therapy and telemedicine, there are many challenges that need to be addressed by the end of the decade to better the lives of chronic kidney disease patients....
Reshaping global health after COVID-19
The COVID-19 pandemic has cast a new light on the compelling necessity of addressing health inequalities across the globe.
Electronic cigarettes and science in EU policy making
Cigarette smoking is responsible for nearly 700,000 deaths in the EU every year and eliminating smoking has been at the core of Europe's Beating Cancer Plan.
The future of nanomedicines in Europe
Nanomedicines are emerging as an innovative technology in the scientific field, as they help address unmet medical needs and offer alternatives for many therapeutic areas. Nanomedicine uses state-of-the-art nanotechnology like nanoparticles, nanorobots or nanoelectronic biosensors for diagnosing or treating cancer,...
Breaking silos in diabetes care
According to available data, 60 million people suffer from diabetes in Europe, a figure expected to rise to 68 million by 2045, while diabetes management already represents as much as 10% of overall health budgets.
Driving progress in Europe’s cancer care
With the advent of the Commission's long-awaited cancer plan rapidly approaching, now more than ever, the impetus is there for EU lawmakers to drive change in Europe's cancer care.
The way forward to an animal-free science
Although the EU remains fully committed to phasing out animal testing, a recent European Commission report has shown that animals are still used in areas such as skin irritation and serious eye damage, areas where alternative methods have reached regulatory acceptance.
Innovation and patients at the core of EU orphan drugs law review
The EU's Orphan Regulation was introduced in 2000 and its main objective was to address the challenge of regulating medicines which treat an estimated 30 million patients with rare diseases across the EU.
Transparency in the race for a COVID vaccine
As the coronavirus crisis continues to have a devasting impact on people’s lives and livelihoods, all eyes are on scientists to deliver on a COVID-19 vaccine. It is widely accepted that a safe and effective vaccine represents our best chance...
Preventing osteoporosis in the EU
Osteoporosis is a chronic condition in which bones become weak and brittle, leading to fractures and breaks which often carry life-debilitating consequences. As well as causing considerable mental and psychological distress, they also severely impair people’s abilities to participate in...
COVID-19 and beyond: Confidence and resilience in vaccine ecosystem
The debate over a rapid but safe and effective vaccine to fight the COVID-19 pandemic has heated up in Europe and worldwide.
Building a stronger EU Health Union: where to start?
The European Union is committed to scaling up its role on public health, at the time when well-known diseases such as cancer and obesity intertwine with new cross-border health threats. Drawing lessons from this year’s pandemic, which exposed flaws in...
Europe’s health after COVID-19
Many EU countries are now experiencing the second wave of the COVID-10 pandemic and it seems that the lack of Europe-wide coordination that marked the first wave is still there.
Rare diseases: Ensuring Europe remains at the forefront of innovation
In the past two decades, a combination of scientific breakthroughs coupled with strong incentive systems has seen considerable progress for rare disease patients, but this innovation has tapered off in recent years.